Oruka Therapeutics (NASDAQ:ORKA) Cut to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Oruka Therapeutics to “sell” from “hold,” contrasting with ten other analysts that rate the stock “buy.” MarketBeat’s consensus remains “Moderate Buy,” with an average price target of $134.30.
• ORKA shares opened at $111.04, up 2.7%, near their 12-month high of $111.37 and substantially above their 50-day and 200-day moving averages. The company recently reported a quarterly loss of $0.55 per share, missing estimates by $0.04.
• Insiders sold 191,406 shares worth approximately $12.65 million over the past three months, while institutional investors own 56.44% of the stock. Oruka is a clinical-stage biotechnology company developing peptide-based cancer therapies, including its Phase 1 lead candidate ONCT-01.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Sunday.

ORKA has been the subject of several other reports. Barclays raised their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an "overweight" rating in a research report on Monday, April 27th. Leerink Partners set a $120.00 price target on Oruka Therapeutics in a research report on Thursday, April 30th. Guggenheim reissued a "buy" rating and issued a $200.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. HC Wainwright restated a "buy" rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Monday, August 3rd. Finally, BTIG Research restated a "buy" rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Oruka Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $134.30.

Oruka Therapeutics Stock Up 2.7%

Oruka Therapeutics stock opened at $111.04 on Friday. The stock has a market cap of $7.35 billion, a price-to-earnings ratio of -54.70 and a beta of -0.34. The business's 50-day simple moving average is $87.52 and its 200 day simple moving average is $62.61. Oruka Therapeutics has a 12-month low of $14.08 and a 12-month high of $111.37.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). As a group, sell-side analysts expect that Oruka Therapeutics will post -2.27 EPS for the current year.

Insider Activity

In other news, Director Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00. Following the completion of the transaction, the director directly owned 73,743 shares of the company's stock, valued at approximately $4,348,624.71. This trade represents a 58.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $59.07, for a total value of $607,830.30. Following the completion of the transaction, the senior vice president directly owned 16,406 shares of the company's stock, valued at approximately $969,102.42. This trade represents a 38.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 191,406 shares of company stock worth $12,653,333 in the last three months. Corporate insiders own 23.49% of the company's stock.

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Oruka Therapeutics in the second quarter valued at approximately $474,916,000. Viking Global Investors LP acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $51,280,000. Deep Track Capital LP grew its position in shares of Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company's stock worth $51,051,000 after buying an additional 735,983 shares during the period. Vanguard Group Inc. increased its stake in shares of Oruka Therapeutics by 38.1% in the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company's stock valued at $74,366,000 after acquiring an additional 676,865 shares in the last quarter. Finally, RTW Investments LP increased its stake in shares of Oruka Therapeutics by 5.8% in the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company's stock valued at $62,382,000 after acquiring an additional 112,499 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company's stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source